charles river

We currently operate

110+ Facilities

IN

20+ Countries

We supported the development of

86%



of the novel FDA-approved drugs in 2021

YOUR PARTNER FOR CELL AND GENE THERAPY RESEARCH AND DEVELOPMENT

Conducted

>900

cell & gene therapy studies in 2020

Supported the development of

10

FDA-approved cell & gene therapies

Acquired

6

companies since 2020 to strengthen our end-to-end cell & gene therapy portfolio

1 out of 2 animal models produced for preclinical research globally comes from Charles River

More than

226,000

animals from 3,600+ unique strains are cared for by our genetically engineered models and services staff in an average week

DISCOVERY • A STRATEGIC PARTNER APPROACH

>430 PATENTS have been generated for our partners since 2001

>85 development candidates have been delivered by our scientists since 2001

SAFETY ASSESSMENT • NO MATTER WHAT DEVELOPMENT GOAL, WE'LL HELP YOU REACH THEM

41,729 reports delivered last year, including nGLP and GLP drafts—final and unaudited

DRAFT FINAL UNAUDITED nGLP GLP

Supported

1,395

IND Programs in the last 12 months

MANUFACTURING AND HUMAN CELLULAR MATERIAL • PROVIDING GMP-COMPLIANT PRODUCTS

More than

26,000

biologic testing reports are sent each year, and 200+ licensed products are supported by our biologics testing solutions team

In 2020,

3 MILLION+

FDA-licensed cartridges were produced for use with our highly flexible Endosafe® rapid testing platforms to meet the needs of a variety of sample throughput and lab configurations

460,000+

Microbial ID reports processed by Charles River Accugenix® in 2020

Providing

100+ GMP

GMP-compliant products to support clinical-phase manufacturing for the development of allogeneic therapies

Supplying GMP-compliant cellular material to

20+

allegeneic and autologous customers

472+

installations of Celsis® rapid microbial detection systems for bioburden testing results in 18–24hrs, rapid sterility release in 6 days

FOUNDED IN 1947